Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PRNP | P04156 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12569062 | 0.93 | NPSR1 (0.41) | KMT2AALDH1A1MEN1MAPTHTT | |
| SCHEMBL12568714 | 0.90 | TBXA2R (0.39) | KMT2AALDH1A1MEN1MAPTHTT | |
| SCHEMBL13051455 | 0.88 | L3MBTL1 (0.46) | KMT2AALDH1A1MEN1MAPTHTT | |
| SCHEMBL10206823 | 0.88 | MAPT (0.44) | KMT2AALDH1A1MEN1MAPTSMN1; SMN2 | |
| SCHEMBL12953758 | 0.87 | POLB (0.40) | KMT2AALDH1A1MEN1MAPTHTT | |
| SCHEMBL12568712 | 0.86 | POLB (0.41) | ALDH1A1MAPTPOLBPTGS2 | |
| SCHEMBL13236208 | 0.86 | ALDH1A1 (0.39) | KMT2AALDH1A1MEN1MAPTHTT | |
| SCHEMBL13051457 | 0.85 | POLB (0.40) | ALDH1A1MAPTPOLBPTGS2 | |
| SCHEMBL13236237 | 0.85 | PTGS2 (0.43) | KMT2AALDH1A1MEN1MAPTHTT | |
| SCHEMBL3464899 | 0.85 | MAPT (0.54) | KMT2AALDH1A1MEN1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3293180-A1 | PROCESS FOR PREPARING [4,6-BIS-DIMETHYLAMINO-2-[4-(4-TRIFLUOROMETHYLBENZOYL-AMINO)BENZYL]PYRIMIDIN-5-YL]ACETIC ACID | Actimis Pharmaceuticals, Inc. (US) | 2018-03-14 | — | — | EP | disclosed |
| EP-3293180-A1 | PROCESS FOR PREPARING [4,6-BIS-DIMETHYLAMINO-2-[4-(4-TRIFLUOROMETHYLBENZOYL-AMINO)BENZYL]PYRIMIDIN-5-YL]ACETIC ACID | Actimis Pharmaceuticals, Inc. (US) | 2018-03-14 | — | — | EP | disclosed |
| EP-2709988-B1 | PROCESS FOR PREPARING [4,6-BIS-DIMETHYLAMINO-2-[4-(4-TRIFLUOROMETHYLBENZOYL-AMINO)BENZYL]PYRIMIDIN-5-YL]ACETIC ACID | BOEHRINGER INGELHEIM INT (DE) | 2017-07-05 | — | — | EP | disclosed |
| EP-2709988-B1 | PROCESS FOR PREPARING [4,6-BIS-DIMETHYLAMINO-2-[4-(4-TRIFLUOROMETHYLBENZOYL-AMINO)BENZYL]PYRIMIDIN-5-YL]ACETIC ACID | BOEHRINGER INGELHEIM INT (DE) | 2017-07-05 | — | — | EP | disclosed |
| US-8859770-B2 | Process for preparing [4,6-bis-dimethylamino-2-[4-(4-trifluoromethylbenzoylamino)benzyl]pyrimidin-5-yl]acetic acid | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| US-8859770-B2 | Process for preparing [4,6-bis-dimethylamino-2-[4-(4-trifluoromethylbenzoylamino)benzyl]pyrimidin-5-yl]acetic acid | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| US-8859770-B2 | Process for preparing [4,6-bis-dimethylamino-2-[4-(4-trifluoromethylbenzoylamino)benzyl]pyrimidin-5-yl]acetic acid | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| US-20140187779-A1 | Process for preparing [4,6-bis-dimethylamino-2-[4-(4-trifluoromethylbenzoylamino)benzyl]pyrimidin-5-yl]acetic acid | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-03 | — | — | US | disclosed |
| US-20140187779-A1 | Process for preparing [4,6-bis-dimethylamino-2-[4-(4-trifluoromethylbenzoylamino)benzyl]pyrimidin-5-yl]acetic acid | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-03 | — | — | US | disclosed |
| US-20140187779-A1 | Process for preparing [4,6-bis-dimethylamino-2-[4-(4-trifluoromethylbenzoylamino)benzyl]pyrimidin-5-yl]acetic acid | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-03 | — | — | US | disclosed |
| EP-2205569-A1 | ALKYLTHIO PYRIMIDINES AS CRTH2 ANTAGONISTS | Actimis Pharmaceuticals, Inc., (US) | 2010-07-14 | — | — | EP | disclosed |
| US-7750014-B2 | Imidazo[1,2-C]pyrimidinylacetic acid derivatives | ACTIMIS PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750014-B2 | Imidazo[1,2-C]pyrimidinylacetic acid derivatives | ACTIMIS PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| WO-2009042138-A9 | ALKYLTHIO PYRIMIDINES AS CRTH2 ANTAGONISTS | ACTIMIS PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| EP-1718649-B1 | IMIDAZO 1,2-C PYRIMIDINYLACETIC ACID DERIVATIVES | ACTIMIS PHARMACEUTICALS INC (US) | 2009-06-10 | — | — | EP | disclosed |
| WO-2009042138-A1 | ALKYLTHIO PYRIMIDINES AS CRTH2 ANTAGONISTS | ACTIMIS PHARMACEUTICALS, INC. (US) | 2009-04-02 | — | — | WO | disclosed |
| US-20090012102-A1 | Imidazo[1,2-C]Pyrimidinylacetic Acid Derivatives | ACTIMIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012102-A1 | Imidazo[1,2-C]Pyrimidinylacetic Acid Derivatives | ACTIMIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20070129355-A1 | G-protein-coupled chemoattractant receptor, expressed on T helper cells antagonists such as [4-(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)-5-pyrimidinyl]acetic acid;, used for the treatment of allergic diseases, inflammatory diseases, eosinophil- and basophil-related diseases | ACTIMIS PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | US | disclosed |
| US-20070129355-A1 | G-protein-coupled chemoattractant receptor, expressed on T helper cells antagonists such as [4-(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)-5-pyrimidinyl]acetic acid;, used for the treatment of allergic diseases, inflammatory diseases, eosinophil- and basophil-related diseases | ACTIMIS PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129355-A1 | G-protein-coupled chemoattractant receptor, expressed on T helper cells antagonists such as [4-(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)-5-pyrimidinyl]acetic acid;, used for the treatment of allergic diseases, inflammatory diseases, eosinophil- and basophil-related diseases | HRH2, HRH1, HRH4 | KMT2A 3678/4885ALDH1A1 1360/4885MEN1 4644/4885 |
| US-20140187779-A1 | Process for preparing [4,6-bis-dimethylamino-2-[4-(4-trifluoromethylbenzoylamino)benzyl]pyrimidin-5-yl]acetic acid | AKR7A2, CYP4B1, CYP3A4 | KMT2A 2036/4885ALDH1A1 23/4885MEN1 806/4885 |
| US-20090012102-A1 | Imidazo[1,2-C]Pyrimidinylacetic Acid Derivatives | HRH2, CCR2, HRH1 | KMT2A 2921/4885ALDH1A1 1532/4885MEN1 4541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.